BofA raised the firm’s price target on Axon (AXON) to $750 from $525 and keeps a Buy rating on the shares. Building on the strong refresh cycle of TASER10 and incremental AI/Software product releases, the firm sees Axon’s top-line growth continuing at over 25% from 2024-26, the analyst tells investors. Axon being the only FedRAMP certified digital evidence vendor leaves the company well positioned to the incoming administration’s priorities, the analyst added.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXON:
- Cantor sees six changes to Nasdaq 100 Index in December rebalance
- Axon awarded Federal Government contract to supply RCMP with cameras
- AXON Stock: Remarkable Growth, but the Valuation Poses Risk
- Axon price target raised to $585 from $387 at Barclays
- Axon price target raised to $610 from $500 at JMP Securities
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
